These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36008505)

  • 21. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy.
    Ahmad M; Jan S
    J Ayub Med Coll Abbottabad; 2012; 24(3-4):10-3. PubMed ID: 24669597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation.
    Kleinmann G; Hauser D; Schechtman E; Landa G; Bukelman A; Pollack A
    Int Ophthalmol; 2008 Feb; 28(1):29-34. PubMed ID: 17619829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage.
    Xu Y; Ye Q; Shen W
    Int J Ophthalmol; 2024; 17(6):1066-1072. PubMed ID: 38895681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Panretinal Photocoagulation Plus Intravitreal Anti-VEGF Treatment Against PRP Alone for Diabetic Retinopathy: A Systematic Review With Meta-Analysis.
    Zhang W; Geng J; Sang A
    Front Endocrinol (Lausanne); 2022; 13():807687. PubMed ID: 35422768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy.
    Wei Q; Zhang T; Jiang R; Chang Q; Zhang Y; Huang X; Gao X; Jin H; Xu G
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5783-5791. PubMed ID: 29117316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Obeid A; Gao X; Ali FS; Talcott KE; Aderman CM; Hyman L; Ho AC; Hsu J
    Ophthalmology; 2018 Sep; 125(9):1386-1392. PubMed ID: 29606377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.
    Ahn J; Woo SJ; Chung H; Park KH
    Ophthalmology; 2011 Nov; 118(11):2218-26. PubMed ID: 21724263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
    Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
    Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Beaulieu WT; Maguire MG; Antoszyk AN; Chow CC; Elman MJ; Jampol LM; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2021 Jul; 139(7):725-733. PubMed ID: 33956075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
    Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
    Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.
    Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM;
    Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.
    Hornan D; Edmeades N; Krishnan R; Khan J; Lochhead J
    Eye (Lond); 2010 Aug; 24(8):1315-9. PubMed ID: 20224599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage.
    Huang YH; Yeh PT; Chen MS; Yang CH; Yang CM
    Retina; 2009 Sep; 29(8):1134-40. PubMed ID: 19672218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal conbercept injections.
    Zhang X; Wu C; Zhou LJ; Dai RP
    Sci Rep; 2018 Mar; 8(1):3972. PubMed ID: 29507304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage.
    Berk Ergun S; Toklu Y; Cakmak HB; Raza S; Simsek S
    Semin Ophthalmol; 2015 May; 30(3):177-80. PubMed ID: 24409948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of intraoperative bevacizumab for prevention of postoperative vitreous hemorrhage in diabetic vitreous hemorrhage.
    Göncü T; Özdek S; Ünlü M
    Eur J Ophthalmol; 2014; 24(1):88-93. PubMed ID: 23787453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Ferenchak K; Duval R; Cohen JA; MacCumber MW
    Retina; 2014 Jun; 34(6):1177-81. PubMed ID: 24457977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage?
    Romano MR; Gibran SK; Marticorena J; Wong D; Heimann H
    Eur J Ophthalmol; 2009; 19(4):618-21. PubMed ID: 19551678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab.
    Hu X; Pan Q; Zheng J; Song Z; Zhang Z
    BMC Ophthalmol; 2019 Sep; 19(1):200. PubMed ID: 31519158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.